AC 45594
(Synonyms: 4-庚氧基苯酚) 目录号 : GC10908
inverse agonist of steroidogenic factor 1 (SF-1)
Cas No.:13037-86-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
AC 45594 is a full inverse agonist of steroidogenic factor 1 (SF-1) with an IC50 value of 50~100 nM [1].
SF-1 is a constitutively nuclear hormone receptor. It is essential to the development of gonadal and adrenal glands. It acts as a shaping factor in sexual differentiation and determination. Its effects are exerted primarily via controlling steroid hormone synthesis [1].
Human adrenocortical H295R/TR SF-1 cells were overexpressing SF-1 in a Dox-inducible fashion. After a 4-day treatment with AC 45594, the proliferation of H295R/TR SF-1 cells cultured in basal conditions was inhibited in a dose-dependent manner. AC 45594 showed maximal effect at 10 µM. SF-1 overexpression induced cell proliferation. In the presence of Dox, incubation with AC 45594 at 1 µM markedly reduced the effect of SF-1 overexpression. Moreover, treatment with AC 45594 increased the percentage of sub-G1 (apoptotic) cells [2]. In human adrenocortical H295 cells, cAMP is able to induce the expression of StAR. This induction is dependent on the presence of SF-1. Incubation with AC 45594 dose-dependently reduced amounts of the StAR mRNA to basal levels. At the protein level, 24 h after the cAMP treatment, StAR was increased by 30-fold. But treatment with AC 45594 completely and dose-dependently reversed the cAMP-dependent activation of StAR [1].
No result regarding the effect of AC 45594 in animal bodies had been found.
References:
[1]. Del Tredici AL, Andersen CB, Currier EA, et al. Identification of the first synthetic steroidogenic factor 1 inverse agonists: pharmacological modulation of steroidogenic enzymes. Molecular pharmacology, 2008, 73(3): 900-908.
[2]. Doghman M, Cazareth J, Douguet D, et al. Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonists. The Journal of Clinical Endocrinology & Metabolism, 2009, 94(6): 2178-2183.
| Cas No. | 13037-86-0 | SDF | |
| 别名 | 4-庚氧基苯酚 | ||
| 化学名 | 4-(heptyloxy)phenol | ||
| Canonical SMILES | OC1=CC=C(C=C1)OCCCCCCC | ||
| 分子式 | C13H20O2 | 分子量 | 208.3 |
| 溶解度 | <20.83mg/ml in DMSO; <20.83mg/ml in ethanol | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.8008 mL | 24.0038 mL | 48.0077 mL |
| 5 mM | 0.9602 mL | 4.8008 mL | 9.6015 mL |
| 10 mM | 0.4801 mL | 2.4004 mL | 4.8008 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet